Immunomedics To Present Updated Clinical Results With Solid-Tumor Antibody-Drug Conjugates At Upcoming Conferences

Immunomedics, Inc.,

today announced that Dr. David M. Goldenberg, Chairman, Chief Scientific Officer, and Chief Medical Officer, will present updated results from Phase 2 clinical trials of the Company's two solid-tumor antibody-drug conjugates (ADCs), isactuzumab govitecan (IMMU-132) and labetuzumab govitecan (IMMU-130), at two upcoming conferences. At the 5th Annual World ADC Summit in San Diego, CA, Dr. Goldenberg will report "Clinical Performance of Moderately-Toxic ADCs Demonstrates Improved Therapeutic Index in Patients with Diverse Metastatic Solid Cancers," in the session on "Early Clinical Development Strategies to Demonstrate Patient Benefit," at 12:00 p.m., Pacific Time, Wednesday, October 29, 2014. In addition, Dr. Goldenberg will give an invited lecture on "Challenging the dogmas: Clinical efficacy of SN38 conjugated antibodies in solid tumours," at the 2014 Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, Spain, hosted by the European Organisation for Research and Treatment of Cancer (EORTC), the National Cancer Institute (NCI), and the American Association for Cancer Research (AACR). The oral presentation is scheduled in the "Antibody-Based Therapies (ADC and others)" Plenary Session at 8:20 a.m., Central European Time, Thursday, November 20, 2014. Cynthia L. Sullivan, President and Chief Executive Officer, commented: "Our founder and chief scientist, Dr. Goldenberg, was invited to present important new Phase 2 trial results with these novel antibody-drug conjugates because our platform technology departs from traditional ADCs by having a high ratio of a moderately cytotoxic drug, SN-38, conjugated to 2 different antibodies that together target most solid cancers. He will report the high therapeutic index of these agents, which is the ability to specifically deliver high and repeated doses with manageable toxicities (mostly neutropenia) in heavily-pretreated patients with metastatic cancers." "We believe our ADC platform may represent a paradigm change in this technology, and we are eager to share these encouraging results in very difficult-to-treat cancers. Together, almost 200 patients have been studied with these two agents," she added.